IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
� Sales by Geographical Region
For the year to March 31 2008, sales gen er ated in Ja pan were up 30% over the pre vi ous year to reach
Yen859 bil lion, com pris ing 62.5% of to tal sales. Sales in Takeda’s sec ond larg est re gion, North Amer ica,
de clined by 16% in the year un der re view, to Yen358 bil lion and now ac count ing for around one quar ter
(26%) of Takeda’s rev e nues. Com pris ing 10.7% of to tal sales, sales in Eu rope de clined by 23% to reach
Yen147 bil lion, while Other Mar kets, com pris ing the re main ing 0.75% of to tal sales, fell by 59% to
Yen25.0 bil lion in the year to March 31 2008.
Yen billions
1000
900
800
700
600
500
400
300
200
100
0
Source: Takeda Annual Reports
Lat est Re sults
Sales by Geographic Region
2004 2005 2006 2007 2008
Japan North America Europe Asia/Other Markets
In the nine months end ing De cem ber 31 2008, Takeda re ported a 7.2% rise in sales to Yen1,203 bil lion,
over the equiv a lent pe riod of 2007. Phar ma ceu ti cal seg ment sales in creased 13.4% to Yen1,134 bil lion
with sales of Eth i cal drugs up 13.9% to Yen1,084 bil lion com pris ing around 40% from Ja pan where Eth i -
cal drug sales in creased 2% to Yen427.1 bil lion and around 60% of sales came from Over seas, up 18.9%
to Yen657 billion.
Sales of in ter na tional stra te gic prod uct Actos (pioglitazone) for di a be tes de creased 4.8% to Yen297.7 bil -
lion (due to ap pre ci a tion of the Yen; an in crease in US$ was re corded) with sales growth from: pep tic ul -
cer drug Prevacid (lansoprazole) with global sales up 97.2% to Yen224.4 bil lion (due to con sol i da tion of
TAP); Blopress (candesartan) up 2.8% to Yen4.8 bil lion and Leuprorelin, up 2.9% to Yen97.8 bil lion.
Growth in Ja pan was also driven by a 42.3% rise in sales of Enbrel (etanercept) for rheu ma toid ar thri tis
al though also saw a de cline in sales of di a be tes drug Basen, down 11.8% to Yen37.1 bil lion. In the US,
the con sol i da tion of TAP and Mil len nium as sub sid iar ies re sulted in the in clu sion of the sales of
lansoprazole and Velcade (for mul ti ple myeloma), con trib ut ing to over all sales growth. The pat ent ex pi -
ra tion of lansoprazole in Europe resulted in a decline in sales in this region
Sales by the Con sumer Healthcare busi ness in creased 3.2% to Yen50.1 bil lion, sup ported by in creased
sales of Benza (a cold rem edy) and Nicorette for smok ing ces sa tion al though sales of vi ta min tonic
(Alinamin) drinks were down. Sales by Other Seg ments de creased by 9.5% in the same pe riod to Yen7.2
billion
Net prof its of Yen169 bil lion were re corded for the nine months, 24.5% lower than in 2007 while Earn ings
per Share dropped to Yen206.95 from Yen389.84 in 2007. In vest ment in Re search and De vel op ment
amounted to Yen207.4 bil lion, 121.8% higher than the pre vi ous year.
© 2009 IMS Health In cor po rated or its af fil i ates Page 18